ARCH Venture Fund XII, L.P.'s Form 4 filing
Prime Medicine, Inc. (PRME) · filed Feb 20, 2024
- Accession no.
- 0001062993-24-003739
- Filed
- Feb 20, 2024, 5:38 PM ET
- Trade date
- Feb 15, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $20.0M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| ARCH Venture Fund XII, L.P.CIK 0001906837 | 10% Owner |
| ARCH Venture Partners XII, LLCCIK 0001979548 | 10% Owner |
| ARCH Venture Partners XII, L.P.CIK 0001979765 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 15, 2024 | Common Stock | PPurchaseAcquired | +3,200,000 | $6.25 | +$20,000,000 | 3,200,000 | Indirect | Duplicate filing |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.